To amend title XVIII of the Social Security Act to extend eligibility for certain payment increases for biosimilar biological products under the Medicare program.
This bill extends a Medicare payment provision that increases reimbursement rates for biosimilar biological products, which are lower-cost alternatives to expensive biologic drugs. Currently, manufacturers of these biosimilars receive higher Medicare payments through 2027, and this legislation pushes that deadline out to 2032, giving them five additional years of enhanced payment eligibility. The change primarily affects pharmaceutical manufacturers that produce biosimilars and the Medicare program's drug payment structure. The bill has no direct funding requirements since it modifies an existing payment mechanism rather than creating new spending. By extending this incentive, the legislation aims to encourage continued development and availability of more affordable biologic drug options for Medicare beneficiaries.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.